Who founded Navrogen?

Navrogen was founded by Nicholas Nicolaides, Luigi Grasso in 2017.

Who are Navrogen's investors?

Navrogen's investors include Ben Franklin Technology Partners.

How much funding has Navrogen raised?

Navrogen has disclosed $12.8M raised across 3 of its 4 known rounds.

Where is Navrogen headquartered?

Navrogen is headquartered in Philadelphia, US.

Navrogen

Philadelphia, US · Founded 2017 · Delaware corporation · 2 known investors

Find your way into Navrogen

57 people in our graph share verified history with the Navrogen team — schools, employers, funds. One of them is your warm intro.

Beni Rovinskiunlockedknows Steven Kyriakos · together at Morphotek, Inc. (overlapped)

×3knows the team · via Liberty Property Trust

×2knows the team · via Delaware County Community College

×4knows the team · via West Chester University of Pennsylvania

×2knows the team · via Università di Catania

Navrogen is a biopharmaceutical company developing therapeutic agents that counter tumor-produced Humoral Immuno-Oncology (HIO) factors linked to suppressed humoral immunity and poor response to immune-mediated anti-cancer therapies. It uses proprietary screening, antibody engineering technologies, and diagnostic assays to identify patients whose tumors produce HIO factors, targeting cancer and immune-related disorders.

Biotech Deep Tech Healthtech Medical Devices

Founders & leadership

Navrogen was founded in 2017 by Nicholas Nicolaides and Luigi Grasso.

Nicholas NicolaidesChief Executive Officer and Co-founder

Luigi Grasso Co-founder · Chief Scientific OfficerLuigi Grasso is co-founder and Chief Scientific Officer of Navrogen, a biopharmaceutical company developing therapeutic antibodies for cancer and immune-related disorders. He previously co-founded Morphotek in 2000, where he served as Chief Scientific Officer and led the development of multiple therapeutic antibody programs including MORAb-202, farletuzumab, amatuximab, and gimsilumab, and is a named inventor on over 60 patents.

Steven Kyriakos VP of Finance and OperationsSteven Kyriakos is VP of Finance and Operations at Navrogen. He has over two decades of finance and accounting experience in the biotech and pharmaceutical sectors, including founding and building the accounting, finance, and HR infrastructure for a biotech startup that was acquired by a global pharmaceutical company for $350M in 2007, and managing financial operations including SOX compliance, government grants, budgeting, and venture capital fundraising.

Investors · 2

Ben Franklin Technology PartnersreportedHarrisburg · $50K – $250K

How we know: funding news · Not right? Tell us

Also in the syndicate · 1

Ben Franklin Technology Partners of South Eastern Pennsylvanialead

Funding

SEC filings, press & company announcements

$12.8M disclosed across 3 of 4 rounds · 2018–2024

Undisclosed amountconvertible note financingSep 2019
Ben Franklin Technology Partners of South Eastern Pennsylvania (lead)
Source ↗

▶$542KraisedJun 2024 · 13 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Allan BedwickDirector
Luigi GrassoExecutive Officer, Director
Nicholas C. NicolaidesExecutive Officer, Director
Leon O Moulder, JrDirector

Offering amount: $1M
Amount sold: $542K
Minimum investment: $5K
Proceeds to insiders: $542K
First sale: Jun 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$9.1MraisedFeb 2023 · 20 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Nicholas C. NicolaidesExecutive Officer, Director
Leon O. Moulder, Jr.Director
Allan BedwickDirector
Luigi GrassoExecutive Officer, Director

Offering amount: $9.3M
Amount sold: $9.1M
First sale: Jul 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.2MraisedSep 2019 · 18 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Nicholas NicolaidesExecutive Officer, Director
Luigi GrassoExecutive Officer, Director
Steven G KyriakosExecutive Officer

Offering amount: $3.2M
Amount sold: $3.2M
Placement agents: NA
First sale: Oct 2018
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Nephrogen7 shared keywordsNephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.

Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Urogen5 shared keywordsUroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology. The company commercializes approved therapies for bladder and upper tract cancers, with additional candidates in development.

Geron5 shared keywordsGeron is a biopharmaceutical company focused on developing therapies for blood cancer. The company has over 30 years of experience in research and clinical development.

Anthrogen4 shared keywordsAnthrogen develops Odyssey, a family of protein language models with 102 billion parameters designed for multi-objective protein design. The models provide an API for researchers and organizations in biotechnology and drug discovery.

Companies competing with Navrogen for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Navrogen Announces the Closing of $3.2M Funding to Support its Humoral Immuno-Oncology Platform Discovery Technologies and Preclinical Pipeline - Navrogen : Navrogennavrogen.com · Sep 2019

Frequently asked questions

What does Navrogen do?: Navrogen is a biopharmaceutical company developing therapeutic agents that counter tumor-produced Humoral Immuno-Oncology (HIO) factors linked to suppressed humoral immunity and poor response to immune-mediated anti-cancer therapies. It uses proprietary screening, antibody engineering technologies, and diagnostic assays to identify patients whose tumors produce HIO factors, targeting cancer and immune-related disorders.
Who founded Navrogen?: Navrogen was founded by Nicholas Nicolaides, Luigi Grasso in 2017.
Who are Navrogen's investors?: Navrogen's investors include Ben Franklin Technology Partners.
How much funding has Navrogen raised?: Navrogen has disclosed $12.8M raised across 3 of its 4 known rounds.
Where is Navrogen headquartered?: Navrogen is headquartered in Philadelphia, US.